Our Services

Cannabis

In accordance with the local jurisdictions the importation, distribution and storage of Cannabis for medical use is permitted if you hold an “IMC-GDP License” which is exclusively issued by the Ministry Of Health. IMP – Clinical Supply Services holds this license.

Cannabis remains a prohibited substance worldwide; therefore, the innovative medicalization process established in Israel requires compliance to strict guidelines issued by the Israeli Medical Cannabis (IMC) unit, Ministry of Health for clinical supply management: Good Agriculture Practice (IMC-GAP), Good Manufacturing Practice (IMC-GMP), Good Distribution Practice (IMC-GDP) and Good Security Practice (IMC-GSP). Adherence to the above guidelines will ensure safe receipt of the Cannabis to the patients participating in clinical trials.

Israel is considered a global leader in research of cannabis for medical purposes. The medicalization process enables the conduct of clinical trials in Israel with cannabis via new usages and dosage forms. IMP’s  IMC-GDP  permit represents a milestone for our company, enhancing our contribution to the increasing amount of clinical trials conducted with Cannabis , for current and future studies in Israel.

Cannabis

In accordance with the local jurisdictions the importation, distribution and storage of Cannabis for medical use is permitted if you hold an “IMC-GDP License” which is exclusively issued by the Ministry Of Health. IMP – Clinical Supply Services holds this license.

Cannabis remains a prohibited substance worldwide; therefore, the innovative medicalization process established in Israel requires compliance to strict guidelines issued by the Israeli Medical Cannabis (IMC) unit, Ministry of Health for clinical supply management: Good Agriculture Practice (IMC-GAP), Good Manufacturing Practice (IMC-GMP), Good Distribution Practice (IMC-GDP) and Good Security Practice (IMC-GSP). Adherence to the above guidelines will ensure safe receipt of the Cannabis to the patients participating in clinical trials.

Israel is considered a global leader in research of cannabis for medical purposes. The medicalization process enables the conduct of clinical trials in Israel with cannabis via new usages and dosage forms. IMP’s  IMC-GDP  permit represents a milestone for our company, enhancing our contribution to the increasing amount of clinical trials conducted with Cannabis , for current and future studies in Israel.